Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Bob Iger Plans Early Exit as Disney Board Prepares CEO Succession Vote 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
REHOVOT, Israel, May 30, 2017 -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that CEO Oded S. Lieberman, PhD will present at the Jefferies Global Healthcare Conference on Wednesday, June 7 at 2:30 pm ET in New York. Dr. Lieberman will give a corporate overview and discuss the company's flagship product candidates designed to treat moderate to severe Parkinson's disease.
To access the live webcast of the presentation, please visit ir.neuroderm.com/. A replay will be available for a limited time following the presentation.
About NeuroDerm
NeuroDerm is a clinical-stage pharmaceutical company developing central nervous system (CNS) product candidates that are designed to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration. NeuroDerm’s main focus is in Parkinson's disease, where it has three clinical stage product candidates in development which offer a solution for almost every Parkinson’s disease patient, from moderate to the very severe stage of the disease. The primary product candidates are a line of levodopa and carbidopa (LD/CD) products administered through small belt pumps that deliver a continuous, controlled dose of LD/CD. The LD/CD product candidates, ND0612L and ND0612H, are aimed at the treatment of moderate and advanced Parkinson’s disease patients, respectively, and are delivered subcutaneously. NeuroDerm is also designing a patch pump for future use. In addition, NeuroDerm is developing ND0701, a novel subcutaneously delivered apomorphine formulation for patients who suffer from moderate to severe Parkinson’s disease and who do not respond well to LD/CD. NeuroDerm is headquartered in the Weizmann Science Park in Rehovot, Israel.
NeuroDerm Contact:
Oded S. Lieberman, PhD, CEO
[email protected]
Tel.: +972-8-946 2729
Cell: +1-617-517 6077
U.S. Investor Contact:
David Carey
Lazar Partners Ltd.
[email protected]
+212-867-1768
